Free Trial
TSE:TST

Telesta Therapeutics (TST) Stock Price, News & Analysis

About Telesta Therapeutics Stock (TSE:TST)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
292,300 shs
Average Volume
212,584 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Telesta Therapeutics Inc. is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer. The Company owns a manufacturing facility for MCNA at Montreal, Quebec. The Company has not generated any revenues.

Receive TST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TST Stock News Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

TST Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Telesta Therapeutics investors own include Comstock (LODE), Bombardier, Inc. Class B (BBD.B), Big Banc Split (BNK), Air Canada (AC), Alliance MMA (AMMA), BioLineRx (BLRX) and Cracker Barrel Old Country Store (CBRL).

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
TSE:TST
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (TSE:TST) was last updated on 3/16/2019 by MarketBeat.com Staff.
From Our Partners